ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Point-of-Care Platelet Function Testing Predicts Bleeding in Patients Exposed to Clopidogrel Undergoing Coronary Artery Bypass Grafting: Verify Pre-Op TIMI 45—A Pilot Study

Tuesday, February 10, 2015

Submitted by

Source

Source Name: Clinical Cardiology

Author(s)

Grant W. Reed, Amit Kumar, Jianping Guo, Sary Aranki, Prem Shekar, Arvind Agnihotri, Andrew O. Maree, Dalton S. McLean, Kenneth Rosenfield and Christopher P. Cannon

Dr. Reed et al from the Cleveland Clinic conducted this prospective study to assess whether VerifyNow point-of-care platelet testing could predict bleeding in 39 patients receiving Plavix and undergoing CABG.  Patients in higher PRU quartiles experienced smaller decreases in hematocrit and less bleeding.  By ROC analysis, a PRU threshold of ≤207 was the optimal threshold for discrimination of major bleeding during surgery, with 85% sensitivity and an 89% NPV.

Question:  Should VerifyNow platelet testing be used as a discriminator for timing of CABG rather than waiting the guideline-recommended 5 days for patients who have received Plavix?

Comments

The VerifyNow testing might also be helpful in candidates with an urgent indication to weigh the individual risk of bleeding against the risk of postponing surgery.

Add comment

Log in or register to post comments